Search Results
Your search for The ,The matches 34595 pages
Showing 7101 - 7150Expert Point of View: Ajay K. Nooka, MD, MPH, FACP
Ajay K. Nooka, MD, MPH, FACP, Associate Professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University, Atlanta, commented on the promising emergence of bispecific T-cell engaging (bispecific) antibodies, as represented by studies presented at the 2021...
Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
Reflecting on the Past 50 Years of Cancer Progress and Looking Ahead to the Next 50 Years of Advances
In December 2021, Nobel laureates, cancer center directors, physicians, scientists, politicians, public health officials, and patient advocates gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to celebrate the 50th anniversary of the signing of the National...
M. Eileen Dolan, PhD, Named Deputy Director of the University of Chicago Medicine Comprehensive Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) has appointed renowned cancer researcher M. Eileen Dolan, PhD, as its Deputy Director. Dr. Dolan, Professor of Medicine at the University of Chicago, has spent the past 8 years working as UCCCC’s Associate Director for Cancer...
ASTRO Issues Clinical Guideline on External-Beam Radiation Therapy for Primary Liver Cancers
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of external-beam radiation therapy (EBRT) to treat adults with primary liver cancers. The guideline, ASTRO’s first for primary liver cancers, is published in Practical Radiation ...
New Guideline Offers Most Comprehensive Summary to Date of Therapies for Brain Metastases
In an effort to synthesize findings from multiple guidelines on various management approaches for brain metastases, ASCO, the Society for Neuro-Oncology (SNO), and the American Society for Radiation Oncology (ASTRO) spearheaded the development of a novel publication to inform and update physician...
Moonshot Expansion Offers Opportunity to Increase Equity in Cancer, Recover Progress on Screening
On February 2, 2022, Howard A. “Skip” Burris III, MD, FACP, FASCO, Board Chair of the Association for Clinical Oncology, issued the following statement: “The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy ...
Amid Health-Care Workforce Shortages, Staffing Guidance Should Ensure Protection of Individuals With Cancer
“In many areas of the United States, the health-care system is facing critical workforce shortages. ASCO encourages public health officials and health-care facilities to follow Centers for Disease Control and Prevention guidelines for managing health-care personnel with SARS–CoV-2 infection or...
ASCO Updates Guidance on Use of Abemaciclib and Endocrine Therapy in Patients With High-Risk Early Breast Cancer
A rapid update to the ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for early breast cancer provides guidance on the use of the oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor abemaciclib with endocrine therapy in patients with high-risk early breast cancer.1 The...
ASCO and American Cancer Society Announce Collaboration to Empower People With Cancer Information They Can Trust
ASCO and the American Cancer Society (ACS) initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer prevention,...
News From the 2022 ASCO Genitourinary Cancers Symposium
The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from...
Expert Point of View: Jenny C. Chang, MD
Jenny C. Chang, MD, the Emily Herrmann Chair in Cancer Research and Director of the Dr. Mary and Ron Neal Cancer Center at Houston Methodist Hospital in Texas, found the results from imaging mass cytometry to be exciting and intriguing.1 The researchers examined “spatial connectivity” among cancer...
Single-Cell Spatial Connectivity Analysis Offers ‘Unprecedented’ Information in Breast Cancer
A next-generation technology that focuses on protein expression at the single-cell level has yielded a wealth of information about “spatial connectivity” between cancer cells and their microenvironment. It also provided information on the benefit of adding the immune checkpoint inhibitor...
Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
On January 25, 2022, tebentafusp-tebn, a bispecific gp100 peptide-HLA–directed CD3 T-cell engager, was approved for treatment of adults with HLA-A*02:01–positive, unresectable or metastatic uveal melanoma.1 Supporting Efficacy Data Approval was based on findings in the open-label, multicenter...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
Improved Outcomes With Time-Limited Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL
Administering time-limitedcombination regimens of venetoclax plus obinutuzumab or venetoclax plus obinutuzumab and ibrutinib was superior to chemoimmunotherapy in achieving undetectable measurable residual disease (MRD) in the peripheral blood at month 15 in fit patients with chronic lymphocytic...
In Case You Missed It: Brief Highlights From the 2021 ASH Annual Meeting & Exposition
COVID has upended our world, and medical conferences have had to adapt to ever-shifting sands depending on the behavior of the variants of the virus that emerge. The 2021 American Society of Hematology (ASH) Annual Meeting & Exposition was no exception, offering a hybrid meeting for in-person...
Study Examines Relationship Between Angiotensin Blockade and Pancreatic Cancer Survival
New research published by Keith et al in BMC Cancer showed that angiotensin blockers—commonly prescribed to treat high blood pressure—may also impact survival in patients with pancreatic cancer. The results are from the largest population-based study of this question and suggest that a broader,...
Expert Point of View: Rona Yaeger, MD
Rona Yaeger, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, discussed the results of the GALAXY trial,1 first putting them into context with previous studies. As she pointed out, the finding of an 11-fold increase in risk of recurrence in patients who...
GALAXY Trial: Circulating Tumor DNA Appears Prognostic in Resected Colorectal Cancer
The use of circulating tumor DNA (ctDNA) assays in early-stage colorectal cancer is highly prognostic for recurrence and may help identify patients who could benefit from adjuvant chemotherapy, according to findings from the GALAXY trial, presented at the 2022 ASCO Gastrointestinal Cancers...
New Data Validate Clinical Utility of Genomic Classifier Test to Help Guide Therapy for Men With Intermediate-Risk Prostate Cancer
New data validating the clinical utility of the Decipher prostate genomic classifier for guiding treatment selection in men with intermediate-risk prostate cancer was presented at the 2022 ASCO Genitourinary Cancers Symposium (Abstract 269). Data from the randomized phase III NRG/RTOG 0126 study,...
(My) German Hodgkin Story
Nearly 200 years ago, Thomas Hodgkin for the first time described a peculiar disease with undulating fever, enlarged lymph nodes, and a big spleen. Its nature was obscure. It was a fatal illness, affecting mainly young adults and children. In 1865, Samuel Wilks named this illness Hodgkin’s...
PARP Inhibitor Plus Abiraterone Benefits Subgroups of Patients With Metastatic Castration-Resistant Prostate Cancer
The combination of the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib plus abiraterone acetate and prednisone as first-line therapy significantly improved radiographic progression-free survival vs abiraterone and placebo alone in men with metastatic castration-resistant prostate cancer...
Researchers Identify Biomarkers That May Help to Predict Response to Immunotherapy for Melanoma
Melanoma is often curable when detected and treated in its early stages. However, the disease can rapidly spread to other organs in the body and become deadly. Immune checkpoint inhibitors have transformed the treatment of certain cancers, including melanoma, and improved patient care. But despite...
Understanding How LGBTQI+ Cancer Survivors Experience Cancer Care
Members of the lesbian, gay, bisexual, transgender, and queer/questioning, intersexed (LGBTQI+) community face numerous challenges and barriers when accessing the health-care system in the United States, including cancer care; as a result, they may be at greater risk for developing cancer and...
Does MRI-Guided Radiotherapy Reduce Treatment-Related Side Effects in Patients With Prostate Cancer?
An interim analysis of an ongoing phase III study indicated that using magnetic resonance imaging (MRI) to guide stereotactic body radiotherapy for patients with prostate cancer reduced side effects associated with the treatment. The findings were presented at the 2022 ASCO Genitourinary Cancers...
Expert Point of View: George D. Demetri, MD, FASCO
ASCO invited comments on the INTRIGUE study from George D. Demetri, MD, FASCO, Professor of Medicine at Harvard Medical School and Director of the Center for Sarcoma and Bone Oncology, Senior Vice President for Experimental Therapeutics, and Quick Family Chair in Medical Oncology at Dana-Farber...
Similar Efficacy but Better Tolerability for Ripretinib vs Sunitinib in Second-Line GIST Therapy
In the INTRIGUE trial, reported during the January 2022 session of the virtual ASCO Plenary Series, the tyrosine kinase inhibitor ripretinib was not superior to sunitinib in the second-line treatment of patients with advanced gastrointestinal stromal tumors (GIST) but was better tolerated.1...
Copanlisib in Patients With PIK3CA-Mutated Tumors
In a phase II trial reported in the Journal of Clinical Oncology, Damodaran et al found that the phosphoinositide 3-kinase (PI3K) inhibitor copanlisib exhibited activity in patients who have tumors with PIK3CA mutations. The study is a subprotocol (Z1F) of the NCI-MATCH ECOG-ACRIN trial (EAY131), a ...
Expert Point of View: Jane N. Winter, MD
Jane N. Winter, MD, moderator of the press conference on late-breaking abstracts at the 2021 American Society of Hematology (ASH) Annual Meeting & Exhibition, commented on the BELINDA study in the context of two investigations that had been previously reported at the same meeting. These two...
Matthew R. Zibelman, MD, on Renal Cell Carcinoma: New Results on Combination of Nivolumab and Axitinib
Matthew R. Zibelman, MD, of Fox Chase Cancer Center, discusses phase I/II results from a study of treatment-naive patients with advanced renal cell carcinoma who received a combination of the immunotherapy (IO) nivolumab and the tyrosine kinase inhibitor (TKI) axitinib. The findings suggest that...
BELINDA: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to the results of the phase III BELINDA trial,...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, called the results of the AGILE study “very promising.” He moderated a press briefing that featured the abstract at the American Society of Hematology (ASH) Annual Meeting & Exposition. “Patients with the...
AGILE: Addition of Ivosidenib to Azacitidine Triples Median Overall Survival in Difficult-to-Treat AML Population
In patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who were ineligible for intensive chemotherapy, the addition of the IDH1 inhibitor ivosidenib to azacitidine significantly improved survival vs azacitidine alone, according to data presented at the 2021 American...
Study Evaluates Effectiveness of Existing Risk Stratification System for Hepatoblastoma
A new study published by Zhou et al in JAMA Network Open independently verified the value of a system that assesses hepatoblastoma risk in children. The researchers also discovered the potential for tumor histology to predict a patient’s hepatoblastoma prognosis. Hepatoblastoma is a rare childhood ...
Expert Point of View: Joshua Brody, MD
Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...
Fixed-Duration Venetoclax Plus Ibrutinib Achieves Deep and Durable MRD Remissions in CLL
Two different trials presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition found that fixed-duration treatment with ibrutinib and venetoclax achieved deep and sustained undetectable measurable residual disease (MRD) status when used as first-line therapy for...
Study Examines Predictive Biomarker for Bladder Cancer Survival
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery are being reported at the 2022 ASCO Genitourinary Cancers Symposium by Thomas W. Flaig, MD, and...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
Improved Outcomes With Time-Limited Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients with CLL
Administering time-limited regimens that were combinations of venetoclax plus obinutuzumab or venetoclax plus obinutuzumab and ibrutinib was superior to chemoimmunotherapy in achieving undetectable measurable residual disease in the peripheral blood at month 15 in fit patients with chronic...
Expert Point of View: Laura C. Michaelis, MD
The moderator of the press briefing on COVID-19 in patients with blood disorders, held during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, was Laura C. Michaelis, MD, a clinician and clinical researcher at the Medical College of Wisconsin, Milwaukee. Dr. Michaelis...
Aggressive Supportive Treatment for COVID-19 May Be Needed in Patients With Hematologic Cancers
New research underscores the need for aggressive support of patients hospitalized with blood cancer and COVID-19, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Two studies of one of the largest data sets of patients with blood cancer...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, said the “fascinating” findings of the study reported by Bouzid et al make it worthy of an ASH Plenary Session...
Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
The antibody-drug conjugate enfortumab vedotin-ejfv is effective in patients with muscle-invasive bladder cancer who are not eligible for cisplatin chemotherapy, according to data from cohort H of the phase IB/II EV-103 clinical trial being presented at the 2022 ASCO Genitourinary Cancers Symposium ...
CHIP Mutations Associated With Lower Risk of Alzheimer’s Disease
The presence of clonal hematopoiesis of indeterminate potential, or CHIP, increases the risk of developing a myeloid malignancy and also cardiovascular disease—which are well-established findings—but it may also protect against developing Alzheimer’s disease, according to findings reported at the ...
Highlights From the 2021 ASH Annual Meeting & Exposition
The ongoing COVID-19 pandemic and successful hybrid format dominated much of the discussion at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, but the lasting impact of the meeting will be the groundbreaking research that was presented. Throughout all diseases,...
Meta-Analysis of Aromatase Inhibitors vs Tamoxifen in Premenopausal Women With ER-Positive Early-Stage Breast Cancer Receiving Ovarian Suppression
In a patient-level meta-analysis reported in The Lancet Oncology, researchers from the Early Breast Cancer Trialists’ Collaborative Group found that use of an aromatase inhibitor vs tamoxifen reduced the risk of recurrence in premenopausal women with estrogen receptor (ER)-positive early breast...
Tofacitinib for Rheumatoid Arthritis: Cancer and Cardiovascular Event Risks
In a phase IIIb/IV safety endpoint trial (ORAL Surveillance) reported in The New England Journal of Medicine, Ytterberg et al found that treatment with the JAK inhibitor tofacitinib for rheumatoid arthritis was associated with higher rates of cancer and major cardiovascular events compared with...
Web-Based Intervention to Manage Symptoms and Quality of Life in Women With Recurrent Ovarian Cancer
In an NRG Oncology/GOG study (GOG-0259) reported in the Journal of Clinical Oncology, Donovan et al found that both nurse-led (Nurse-WRITE) and self-directed (SD-WRITE) Web-based symptom self-management interventions (WRITE Symptoms) improved symptom control vs enhanced usual care alone in women...
Centralizing Care for Adolescents and Young Adults With Cancer to Improve Long-Term Survivorship
This past fall, Memorial Sloan Kettering (MSK) Cancer Center in New York expanded its adolescent and young adult (AYA) program with the establishment of the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers. The Stuart Center is now part of the increasing list of about 50 academic ...
